{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:51:45Z","timestamp":1740124305764,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To evaluate feasibility, frequency and severity of peri-procedural complications and post-procedural adverse events (AEs) in patients with advanced cholangiocarcinoma or liver metastasis of uveal melanoma and prior hemihepatectomy undergoing chemosaturation percutaneous hepatic perfusion (CS-PHP) and to analyze therapy response and overall survival compared to a matched group without prior surgery. CS-PHP performed between 10\/2014 and 02\/2018 were retrospectively assessed. To determine peri-procedural safety and post-procedural adverse events, hospital records and hematological, hepatic and biliary function were categorized using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (1\u20135; mild-death). Significance was tested using Wilcoxon signed-rank and Mann\u2013Whitney U test. Kaplan\u2013Meier estimation and log-rank test assessed survival. Overall 21 CS-PHP in seven patients (4\/7 males; 52\u2009\u00b1\u200910\u00a0years) with hemihepatectomy (group<jats:sup>hemihep<\/jats:sup>) and 22 CS-PHP in seven patients (3\/7 males; 63\u2009\u00b1\u200912\u00a0years) without prior surgery (group<jats:sup>noresection<\/jats:sup>) were included. No complications occurred during the CS-PHP procedures. Transient changes (CTCAE grade 1\u20132) of liver enzymes and blood cells followed all procedures. In comparison, group<jats:sup>hemihep<\/jats:sup> presented slightly more AEs grade 3\u20134 (e.g. thrombocytopenia in 57% (12\/21) vs. 41% (9\/22; p\u2009=\u20090.37)) 5\u20137\u00a0days after CS-PHP. These AEs were self-limiting or responsive to treatment (insignificant difference of pre-interventional to 21\u201345\u00a0days post-interventional values (p\u2009&gt;\u20090.05)). One patient in group<jats:sup>hemihep<\/jats:sup> with high tumor burden died eight days following CS-PHP. No deaths occurred in group<jats:sup>noresection<\/jats:sup>. In comparison, overall survival after first diagnosis was insignificantly shorter in group<jats:sup>noresection<\/jats:sup> (44.7(32\u201356.1) months) than in group<jats:sup>hemihep<\/jats:sup> (48.3(34.6\u201372.8) months; p\u2009=\u20090.48). The severity of adverse events following CS-PHP in patients after hemihepatectomy was comparable to a matched group without prior liver surgery. Thus, the performance of CS-PHP is not substantially compromised by a prior hemihepatectomy.<\/jats:p>","DOI":"10.1007\/s10585-020-10057-9","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T14:02:47Z","timestamp":1602252167000},"page":"683-692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery"],"prefix":"10.1007","volume":"37","author":[{"given":"C. L. A.","family":"Dewald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. K.","family":"Maschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. C.","family":"Meine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. A.","family":"Alten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M.","family":"Kirstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. K.","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. C.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0135-7082","authenticated-orcid":false,"given":"J. B.","family":"Hinrichs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"issue":"4","key":"10057_CR1","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1007\/s00330-018-5729-z","volume":"29","author":"S Marquardt","year":"2019","unstructured":"Marquardt S, Kirstein MM, Br\u00fcning R, Zeile M, Ferrucci PF, Prevoo W et al (2019) Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: european multicentre study on safety, short-term effects and survival. Eur Radiol 29(4):1882\u20131892","journal-title":"Eur Radiol"},{"issue":"8","key":"10057_CR2","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00262-019-02371-3","volume":"68","author":"M-X Tian","year":"2019","unstructured":"Tian M-X, Zhou Y-F, Qu W-F, Liu W-R, Jin L, Jiang X-F et al (2019) Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy. Cancer Immunol Immunother 68(8):1369\u20131378","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"10057_CR3","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/bjs.8953","volume":"99","author":"L Sulpice","year":"2012","unstructured":"Sulpice L, Rayar M, Boucher E, Pracht M, Meunier B, Boudjema K (2012) Treatment of recurrent intrahepatic cholangiocarcinoma. Br J Surg Dezember 99(12):1711\u20131717","journal-title":"Br J Surg Dezember"},{"issue":"3","key":"10057_CR4","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1007\/s00464-017-5834-0","volume":"32","author":"DL Aghayan","year":"2018","unstructured":"Aghayan DL, Kazaryan AM, Fretland \u00c5A, Sahakyan MA, R\u00f8sok BI, Bj\u00f8rnbeth BA et al (2018) Laparoscopic liver resection for metastatic melanoma. Surg Endosc 32(3):1470\u20131477","journal-title":"Surg Endosc"},{"issue":"5","key":"10057_CR5","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1245\/ASO.2006.01.016","volume":"13","author":"TM Pawlik","year":"2006","unstructured":"Pawlik TM, Zorzi D, Abdalla EK, Clary BM, Gershenwald JE, Ross MI et al (2006) Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 13(5):712\u2013720","journal-title":"Ann Surg Oncol"},{"key":"10057_CR6","doi-asserted-by":"publisher","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","volume":"27","author":"JW Valle","year":"2016","unstructured":"Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D (2016) Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v28\u201337","journal-title":"Ann Oncol"},{"key":"10057_CR7","unstructured":"S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms, Version 3.2, AWMF, Register-Nummer: 032\/024OL. 2019."},{"issue":"7","key":"10057_CR8","first-page":"1230","volume":"6","author":"P Jovanovic","year":"2013","unstructured":"Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V (2013) Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol 6(7):1230\u20131244","journal-title":"Int J Clin Exp Pathol"},{"issue":"4","key":"10057_CR9","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","volume":"23","author":"MS Hughes","year":"2016","unstructured":"Hughes MS, Zager J, Faries M, Alexander HR, Royal RE, Wood B et al (2016) Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol 23(4):1309\u20131319","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"10057_CR10","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1200\/JCO.2005.00.927","volume":"23","author":"JF Pingpank","year":"2005","unstructured":"Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW et al (2005) Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. JCO 23(15):3465\u20133474","journal-title":"JCO"},{"issue":"10","key":"10057_CR11","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s00432-017-2461-z","volume":"143","author":"MM Kirstein","year":"2017","unstructured":"Kirstein MM, Marquardt S, Jedicke N, Marhenke S, Koppert W, Manns MP et al (2017) Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors. J Cancer Res Clin Oncol 143(10):2113\u20132121","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"10057_CR12","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00270-019-02243-4","volume":"42","author":"CLA Dewald","year":"2019","unstructured":"Dewald CLA, Meine TC, Winther HMB, Kloeckner R, Maschke SK, Kirstein MM et al (2019) Chemosaturation percutaneous hepatic perfusion (CS-PHP) with melphalan: evaluation of 2D-perfusion angiography (2D-PA) for leakage detection of the venous double-balloon catheter. Cardiovasc Intervent Radiol 42(10):1441\u20131448","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10057_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03289-5","author":"L Sch\u00f6nfeld","year":"2020","unstructured":"Sch\u00f6nfeld L, Hinrichs JB, Marquardt S, Voigtl\u00e4nder T, Dewald C, Koppert W et al (2020) Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. J Cancer Res Clin Oncol. https:\/\/doi.org\/10.1007\/s00432-020-03289-5","journal-title":"J Cancer Res Clin Oncol"},{"key":"10057_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, Ford R, Gwyther S, Mandrekar S et al (2016) RECIST 1.1\u2014update and clarification: from the RECIST committee. Eur J Cancer 62:132\u2013137","journal-title":"Eur J Cancer"},{"issue":"12","key":"10057_CR15","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1007\/s12325-016-0424-4","volume":"33","author":"A Vogel","year":"2016","unstructured":"Vogel A, Gupta S, Zeile M, von Haken R, Br\u00fcning R, Lotz G et al (2016) Chemosaturation percutaneous hepatic perfusion: a systematic review. Adv Ther 33(12):2122\u20132138","journal-title":"Adv Ther"},{"issue":"3","key":"10057_CR16","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00270-013-0826-5","volume":"37","author":"FM Moeslein","year":"2014","unstructured":"Moeslein FM, McAndrew EG, Appling WM, Hryniewich NE, Jarvis KD, Markos SM et al (2014) Evaluation of delcath systems\u2019 generation 2 (GEN 2) melphalan hemofiltration system in a porcine model of percutaneous hepatic perfusion. Cardiovasc Intervent Radiol 37(3):763\u2013769","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"8","key":"10057_CR17","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1007\/s00270-017-1630-4","volume":"40","author":"EM de Leede","year":"2017","unstructured":"de Leede EM, Burgmans MC, Meijer TS, Martini CH, Tijl FGJ, Vuyk J et al (2017) Prospective clinical and pharmacological evaluation of the delcath system\u2019s second-generation (GEN2) hemofiltration system in patients undergoing percutaneous hepatic perfusion with melphalan. Cardiovasc Intervent Radiol 40(8):1196\u20131205","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"10057_CR18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000367715","volume":"1","author":"PL Triozzi","year":"2015","unstructured":"Triozzi PL, Singh AD (2015) Adjuvant therapy of uveal melanoma: current status. Ocul Oncol Pathol 1(1):54\u201362","journal-title":"Ocul Oncol Pathol"},{"issue":"8","key":"10057_CR19","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","volume":"30","author":"L Khoja","year":"2019","unstructured":"Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E et al (2019) Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol 30(8):1370\u20131380","journal-title":"Ann Oncol"},{"issue":"10","key":"10057_CR20","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1055\/s-0034-1366081","volume":"186","author":"T Vogl","year":"2014","unstructured":"Vogl T, Zangos S, Scholtz J, Schmitt F, Paetzold S, Trojan J et al (2014) Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two european centers. Fortschr R\u00f6ntgenstr 186(10):937\u2013944","journal-title":"Fortschr R\u00f6ntgenstr"},{"issue":"6","key":"10057_CR21","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/jso.24956","volume":"117","author":"I Karydis","year":"2018","unstructured":"Karydis I, Gangi A, Wheater MJ, Choi J, Wilson I, Thomas K et al (2018) Percutaneous hepatic perfusion with melphalan in uveal melanoma: a safe and effective treatment modality in an orphan disease. J Surg Oncol 117(6):1170\u20131178","journal-title":"J Surg Oncol"},{"issue":"8","key":"10057_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/COC.0000000000000356","volume":"41","author":"AM Abbott","year":"2018","unstructured":"Abbott AM, Doepker MP, Kim Y, Perez MC, Gandle C, Thomas KL et al (2018) Hepatic progression-free and overall survival after regional therapy to the liver for metastatic melanoma. Am J Clin Oncol 41(8):747\u2013753","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10057_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40644-019-0218-4","volume":"19","author":"C Artzner","year":"2019","unstructured":"Artzner C, Mossakowski O, Hefferman G, Grosse U, Hoffmann R, Forschner A et al (2019) Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. Cancer Imaging 19(1):31","journal-title":"Cancer Imaging"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-020-10057-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-020-10057-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-020-10057-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T07:01:10Z","timestamp":1633849270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-020-10057-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10057"],"URL":"https:\/\/doi.org\/10.1007\/s10585-020-10057-9","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"type":"print","value":"0262-0898"},{"type":"electronic","value":"1573-7276"}],"subject":[],"published":{"date-parts":[[2020,10,9]]},"assertion":[{"value":"13 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors of this manuscript declare relationships with the following companies: Siemens Healthcare and ProMedicus (Bernhard Meyer and Frank Wacker; outside the submitted work). The remaining authors declare no relationships with any companies whose products or services may be related to the subject matter of the article. All authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}